The Effects of Disease-Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis.

ABSTRACT:

Background

Retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thinning are used as markers of subclinical retinal degeneration to evaluate the effect of disease-modifying therapies (DMTs) on disease progression in clinical trials of multiple sclerosis (MS). This study aimed to assess the available evidence regarding the effects of DMTs on retinal thinning in people with MS.

Methods

Databases were searched for studies reporting longitudinal optical coherence tomography (OCT)-derived annualized RNFL and GCIPL thinning in patients receiving DMTs treatment. The standardized mean differences (Hedges g) of RNFL and GCIPL thickness between the baseline and follow-up were used as the primary effect size measure. DMTs were divided into moderate (M-DMTs)

SUBMITTER: Zhang X 

PROVIDER: S-EPMC11883414 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature